Cancer cachexia: Understanding the molecular basis

Nature Reviews Cancer

Volumn 14, Issue 11, 2014, Pages 754-762

  Argilés, Josep M ^a   Busquets, Sílvia ^a   Stemmler, Britta ^b   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BS Nutrition Centre   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCLE PROTEIN;

BODY FAT; CACHEXIA; CALORIC INTAKE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; ENERGY BALANCE; ENERGY EXPENDITURE; HUMAN; MUSCLE ATROPHY; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW; SKELETAL MUSCLE; WASTING SYNDROME; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; COMPLICATION; METABOLISM; MITOCHONDRION; NEOPLASM;

ADIPOSE TISSUE; ANIMALS; CACHEXIA; HUMANS; MITOCHONDRIA; MUSCLE, SKELETAL; NEOPLASMS;

EID: 84908245468     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3829     Document Type: Review

References (108)

1. Evans, W. J. et al. Cachexia: a new definition. Clin. Nutr. 27, 793-799 (2008).
2. Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489-495 (2011).
3. Argilés, J. M. et al. Consensus on cachexia definitions. J. Am. Med. Dir. Assoc. 11, 229-230 (2010).
4. Warren, S. The inmediate cause of death in cancer. Am. J. Med. Sci. 184, 610-613 (1932).
5. Dewys, W. D. et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69, 491-497 (1980).
6. Teunissen, S. C. C. M. et al. Symptom prevalence in patients with incurable cancer: a systematic review. J. Pain Symptom Manage. 34, 94-104 (2007).
7. Blum, D. et al. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25, 1635-1642 (2014).
8. Blum, D. et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer 18, 273-279 (2010).
9. Bozzetti, F. & Mariani, L. Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN. J. Parenter. Enteral Nutr. 33, 361-367.
10. Vigano, A. L. et al. The Abridged Patient-Generated Subjective Global Assessment Is a Useful Tool for Early Detection and Characterization of Cancer Cachexia. J. Acad. Nutr. Diet. 114, 1088-1098 (2014).
11. Argilés, J. M. et al. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J. Cachexia. Sarcopenia Muscle 2, 87-93 (2011).
12. Busquets, S. et al. Staging cachectic cancer patients using the cachexia score (CASCO). Communication 3-03. Abstracts of the 7th cachexia conference, kobe/osaka, Japan, december 9-11, 2013. J. Cachexia. Sarcopenia Muscle 4, 295-343 (2013).
13. Tisdale, M. J. Catabolic mediators of cancer cachexia. Curr. Opin. Support. Palliat. Care 2, 256-261 (2008).
14. Argilés, J. M., Busquets, S., Toledo, M. & López-Soriano, F. J. The role of cytokines in cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 263-268 (2009).
15. Scheede-Bergdahl, C. et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin. Nutr. 31, 85-88 (2012).
16. Punzi, T. et al. C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol. Diagn. Ther. 16, 115-124 (2012).
17. Weber, M.-A. et al. Myoglobin plasma level related to muscle mass and fiber composition: a clinical marker of muscle wasting? J. Mol. Med. 85, 887-896 (2007).
18. Argilés, J. M. et al. Targets in clinical oncology: the metabolic environment of the patient. Front. Biosci. 12, 3024-3051 (2007).
19. Evans, W. K. et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 45, 3347-3353 (1985).
20. Constantinou, C. et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27, 15-24 (2011).
21. Sanders, P. M. & Tisdale, M. J. Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett. 212, 71-81 (2004).
22. Busquets, S. et al. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett. 579, 717-722 (2005).
23. Collins, P., Bing, C., McCulloch, P. & Williams, G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br. J. Cancer 86, 372-375 (2002).
24. Tzika, A. A. et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int. J. Oncol. 43, 886-894 (2013).
25. Antunes, D. et al. Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting. Biochim. Biophys. Acta 1841, 896-905 (2014).
26. Fermoselle, C. et al. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice. Exp. Physiol. 98, 1349-1365 (2013).
27. Shum, A. M. et al. Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY) 4, 133-143 (2012).
28. Padrão, A. I. et al. Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. Int. J. Biochem. Cell Biol. 45, 1399-1409 (2013).
29. Fuster, G. et al. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of β2-adrenergic agonists. Cancer Res. 67, 6512-6519 (2007).
30. Kang, C., Chung, E., Diffee, G. & Ji, L. L. Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: role of PGC-1α. Exp. Gerontol. 48, 1343-1350 (2013).
31. Puigserver, P. et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol. Cell 8, 971-982 (2001).
32. Miura, S. et al. Overexpression of peroxisome proliferator-activated receptor γ co-activator-1α leads to muscle atrophy with depletion of ATP. Am. J. Pathol. 169, 1129-1139 (2006).
33. Dirksen, R. T. Sarcoplasmic reticulum-mitochondrial through-space coupling in skeletal muscle. Appl. Physiol. Nutr. Metab. 34, 389-395 (2009).
34. Rossi, A. E., Boncompagni, S. & Dirksen, R. T. Sarcoplasmic reticulum-mitochondrial symbiosis: bidirectional signaling in skeletal muscle. Exerc. Sport Sci. Rev. 37, 29-35 (2009).
35. Fontes-Oliveira, C. C. et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency? Biochim. Biophys. Acta 1830, 2770-2778 (2013).
36. Zorzano, A. Regulation of mitofusin-2 expression in skeletal muscle. Appl. Physiol. Nutr. Metab. 34, 433-439 (2009).
37. Cosper, P. F. & Leinwand, L. A. Myosin heavy chain is not selectively decreased in murine cancer cachexia. Int. J. Cancer 130, 2722-2727 (2012).
38. Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539-1547 (2013).
39. Fearon, K., Arends, J. & Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. Nature Rev. Clin. Oncol. 10, 90-99 (2013).
40. Le Bricon, T., Gugins, S., Cynober, L. & Baracos, V. E. Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44, 1340-1348 (1995).
41. Argilés, J. M. & López-Soriano, F. J. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol. Sci. 17, 223-226 (1996).
42. Hasselgren, P.-O., Wray, C. & Mammen, J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem. Biophys. Res. Commun. 290, 1-10 (2002).
43. Smith, I. J. et al. Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. Muscle Nerve 43, 410-414 (2011).
44. Tardif, N., Klaude, M., Lundell, L., Thorell, A. & Rooyackers, O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am. J. Clin. Nutr. 98, 1485-1492 (2013).
45. Krawiec, B. J., Frost, R. A., Vary, T. C., Jefferson, L. S. & Lang, C. H. Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 289, E969-E980 (2005).
46. Mammucari, C. et al. FOXO3 controls autophagy in skeletal muscle in vivo. Cell. Metab. 6, 458-471 (2007).
47. Egerman, M. A. & Glass, D. J. Signaling pathways controlling skeletal muscle mass. Crit. Rev. Biochem. Mol. Biol. 49, 59-68.
48. Glass, D. J. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13, 225-229 (2010).
49. Clarke, B. A. et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell. Metab. 6, 376-385 (2007).
50. Cohen, S. et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083-1095 (2009).
51. Cai, D. et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119, 285-298 (2004).
52. Moore-Carrasco, R. et al. The AP-1/NF-κB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int. J. Oncol. 30, 1239-1245 (2007).
53. He, W. A. et al. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123, 4821-4835 (2013).
54. Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/AKT/mTOR and PI(3)K/AKT/GSK3 pathways. Nature Cell Biol. 3, 1009-1013 (2001).
55. Sandri, M. et al. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (2004).
56. Argilés, J. M., Orpí, M., Busquets, S. & López-Soriano, F. J. Myostatin: more than just a regulator of muscle mass. Drug Discov. Today 17, 702-709 (2012).
57. Hitachi, K. & Tsuchida, K. Role of microRNAs in skeletal muscle hypertrophy. Front. Physiol. 4, 408 (2013).
58. He, W. A. et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl Acad. Sci. USA 111, 4525-4529 (2014).
59. Kulyté, A. et al. MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 306, E267-E274 (2014).
60. Argilés, J. M., López-Soriano, J., Almendro, V., Busquets, S. & López-Soriano, F. J. Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med. Res. Rev. 25, 49-65 (2005).
61. Dalamaga, M. Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications. World J. Exp. Med. 3, 26-33 (2013).
62. Argilés, J. M., López-Soriano, F. J. & Busquets, S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr. Opin. Support. Pal. Care. 1, 293-298 (2007).
63. Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333, 233-238 (2011).
64. Stephens, N. A. et al. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle 2, 111-117 (2011).
65. Petruzzelli, M. et al. A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell. Metab. 20, 433-447 (2014).
66. Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513, 100-104 (2014).
67. Tsoli, M. et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 72, 4372-4382 (2012).
68. Bing, C. et al. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res. 60, 2405-2410 (2000).
69. Virtanen, K. A. et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360, 1518-1525 (2009).
70. Bauwens, M. et al. Molecular imaging of brown adipose tissue in health and disease. Eur. J. Nucl. Med. Mol. Imaging 41, 776-791 (2014).
71. Argiles, J. M., Lopez-Soriano, F. J. & Busquets, S. Counteracting inflammation: a promising therapy in cachexia. Crit. Rev. Oncog. 17, 253-262 (2012).
72. Klein, G. L., Petschow, B. W., Shaw, A. L. & Weaver, E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr. Opin. Support. Palliat. Care 7, 361-367 (2013).
73. Tisdale, M. J. Are tumoral factors responsible for host tissue wasting in cancer cachexia? Future Oncol. 6, 503-513 (2010).
74. Chen, J. L. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711-1723 (2014).
75. Lokireddy, S. et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem. J. 446, 23-36 (2012).
76. Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543 (2010).
77. Busquets, S. et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle 3, 37-43 (2012).
78. Braun, T. P. et al. Cancer-and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. 27, 3572-3582 (2013).
79. Molfino, A., Laviano, A. & Rossi Fanelli, F. Contribution of anorexia to tissue wasting in cachexia. Curr. Opin. Support Palliat Care 4, 249-253 (2010).
80. McGreevy, J. et al. Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer. Support. Care Cancer 22, 2635-2644 (2014).
81. Ramos, E. J. B. et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr. Opin. Clin. Nutr. Metab. Care 7, 427-434 (2004).
82. Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N. & Inui, A. Cancer cachexia-pathophysiology and management. J. Gastroenterol. 48, 574-594 (2013).
83. Prado, C. M. M., Antoun, S., Sawyer, M. B. & Baracos, V. E. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Clin. Nutr. Metab. Care 14, 250-254 (2011).
84. Oberholzer, R. et al. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J. Pain Symptom Manage. 46, 77-95 (2013).
85. Joppa, M. A., Gogas, K. R., Foster, A. C. & Markison, S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28, 636-642 (2007).
86. Cheung, W. W. & Mak, R. H. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease. Am. J. Physiol. Renal Physiol. 303, F1315-F1324 (2012).
87. Bindels, L. B. et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS ONE 7, e37971 (2012).
88. Bindels, L. B. & Delzenne, N. M. Muscle wasting: the gut microbiota as a new therapeutic target? Int. J. Biochem. Cell Biol. 45, 2186-2190 (2013).
89. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489 (2006).
90. Wang, H. S., Oh, D. S., Ohning, G. V. & Pisegna, J. R. Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors. J. Mol. Neurosci. 33, 225-231 (2007).
91. Kerem, M. et al. Adipokines and ghrelin in gastric cancer cachexia. World J. Gastroenterol. 14, 3633-3641 (2008).
92. Takahashi, M. et al. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int. J. Clin. Oncol. 14, 315-320 (2009).
93. Karapanagiotou, E. M. et al. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer 66, 393-398 (2009).
94. Sheriff, S. et al. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol. Cell. Endocrinol. 351, 286-295 (2012).
95. Reano, S., Graziani, A. & Filigheddu, N. Acylated and unacylated ghrelin administration to blunt muscle wasting. Curr. Opin. Clin. Nutr. Metab. Care 17, 236-240 (2014).
96. Yu, A. P. et al. Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle. Acta Physiol. 211, 201-213 (2014).
97. Roxburgh, C. S. & McMillan, D. C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Futur. Oncol. 6, 149-163 (2010).
98. Proctor, M. J. et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer 104, 726-734 (2011).
99. Dumas, J. F. et al. Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis. J. Hepatol. 54, 320-327 (2011).
100. Eschenhagen, T. et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13, 1-10 (2011).
101. Olivan, M. et al. Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutr. Metab. 9, 76 (2012).
102. Tian, M. et al. Cardiac alterations in cancer-induced cachexia in mice. Int. J. Oncol. 37, 347-353 (2010).
103. Drott, C. & Lundholm, K. Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. J. Surg. Res. 49, 62-68 (1990).
104. Mühlfeld, C. et al. Cancer induces cardiomyocyte remodeling and hypoinnervation in the left ventricle of the mouse heart. PLoS ONE. 6, e20424 (2011).
105. Hyltander, A., Drott, C., Körner, U., Sandström, R. & Lundholm, K. Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer. 27, 9-15 (1991).
106. Isenring, E. A. & Teleni, L. Nutritional counseling and nutritional supplements: a cornerstone of multidisciplinary cancer care for cachectic patients. Curr. Opin. Support. Palliat. Care 7, 390-395 (2013).
107. Currow, D. C. & Abernethy, A. P. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 10, 789-802 (2014).
108. Dalton, J. T., Taylor, R. P., Mohler, M. L. & Steiner, M. S. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr. Opin. Support. Palliat. Care 7, 345-351 (2013).